Fortis Healthcare FY26 profit jumps 31% to ₹1,064 cr

FY26 numbers set the tone

Fortis Healthcare announced its financial results for the fiscal year ended March 31, 2026 (FY26), reporting higher revenue and profit compared with FY25. Consolidated revenue from operations rose 17% to ₹9,127.84 crore from ₹7,782.75 crore. Profit for the year increased 31% to ₹1,064.19 crore from ₹809.38 crore in the previous year. Alongside operating performance, the group recorded an exceptional loss of ₹22.24 crore. The exceptional line item included a ₹55.18 crore impact from new labour codes, as stated in the results summary.

Exceptional items: labour-code impact highlighted

The presence of an exceptional loss, despite profit growth, is an important detail for investors tracking underlying performance. Fortis Healthcare said the exceptional loss of ₹22.24 crore included a ₹55.18 crore impact from new labour codes. The numbers indicate that exceptional items were not a simple one-off gain in FY26, but reflected specific accounting or policy impacts during the year. For readers comparing year-on-year profit, this disclosure helps separate operational improvement from non-operating adjustments. It also signals that policy-related cost recognition can appear in reported earnings even when revenue growth remains steady.

Q1 FY26: revenue up 16.6%, margins improved

In Q1 FY26 (quarter ended June 2025), Fortis reported consolidated revenue of ₹2,166.72 crore, up 16.56% year-on-year versus ₹1,858.90 crore. The company also reported operating EBITDA of ₹491 crore, up 43.2% versus ₹343 crore in the comparable period, with EBITDA margin improving to 22.6% from 18.4%. Profit after tax (PAT) for the quarter was reported at ₹260.28 crore in the tabular disclosure, up 56.83% from ₹165.96 crore. Another cited figure in the provided data set put June-quarter consolidated net profit at ₹266.78 crore versus ₹173.98 crore a year earlier, reflecting the same direction of growth.

Hospital business: higher occupancy and ARPOB support growth

The hospital segment remained the main contributor, described as contributing 85% of consolidated revenue. Hospital business revenue increased 18.6% year-on-year to ₹1,838 crore in Q1 FY26 from ₹1,549 crore in Q1 FY25. Hospital operating EBITDA was ₹406 crore with a margin of 22.1%, compared with 18.5% in the year-ago period. Occupancy improved to 69% from 67% in Q1 FY25, according to the reported operational metrics. Average revenue per occupied bed (ARPOB) was stated to have increased 10.2% to ₹2.65 crore per annum. The same disclosure linked ARPOB improvement with a 28% growth in oncology and a 75% increase in robotic surgeries.

Diagnostics: modest revenue growth, sharper margin lift

Fortis’s diagnostics business posted slower top-line growth than hospitals but delivered a clear profitability improvement in the quarter. Diagnostics net revenue was ₹329 crore, a 6.3% year-on-year increase, while gross revenue was ₹369 crore, up 7.4%. Diagnostics operating EBITDA margin improved to 23% from 16.1% in Q1 FY25, as per the stated comparison. Test volumes were reported at 10.1 million for the quarter. The dataset also referenced Agilus Diagnostics revenue at ₹368.8 crore, reflecting a 7.54% increase compared with ₹343.5 crore in Q1 FY25.

Q2 and Q3 FY26: steady double-digit revenue growth

The quarterly trajectory in FY26 remained supportive, based on the reported Q2 and Q3 updates. For Q2 FY26, consolidated revenues were ₹2,331 crore, up 17.3% year-on-year, with operating EBITDA margin at 23.9% versus 21.9% in Q2 FY25. Profit after tax in Q2 FY26 was ₹329 crore, up 70.3% year-on-year. Hospital business revenue in Q2 FY26 was ₹1,974 crore, up 19.3% year-on-year, with hospital operating EBITDA margin at 22.9% versus 21.4%.

For Q3 FY26, Fortis reported consolidated revenues of ₹2,265 crore, up 17.5% year-on-year. The operating EBITDA margin for Q3 FY26 expanded to 22.3% from 19.4%, indicating continued margin improvement through the year.

Q4 FY26: revenue and profit growth continued

For Q4 FY26, revenue from operations was reported at ₹2,364.67 crore, up 17.8% year-on-year from ₹2,007.20 crore and up 4.4% quarter-on-quarter from ₹2,265.01 crore. Total income in Q4 FY26 was ₹2,369.06 crore, up 16.9% year-on-year from ₹2,027.00 crore and up 4.2% quarter-on-quarter from ₹2,273.30 crore. Net profit from continuing operations for Q4 FY26 was ₹271.19 crore, up 44.2% year-on-year from ₹188.02 crore and up 37.4% quarter-on-quarter from ₹197.40 crore. The healthcare segment’s revenue from operations in Q4 FY26 was ₹2,023.23 crore, up 18.9% year-on-year and 4.4% quarter-on-quarter.

Key figures at a glance

Market reaction: mixed on different sessions

The share price reaction in the provided dataset was mixed across references. One update said Fortis Healthcare jumped 4.38% to ₹895.30 after the company reported the June-quarter numbers. Another update stated that the stock fell 1.12% and closed at ₹857.70 on the exchanges on the day it reported Q1 performance. Together, these references underline that short-term price moves can differ by session and context, even when headline earnings growth is strong.

Why these results matter for investors

The FY26 picture combines double-digit revenue growth with a meaningful rise in annual profit, backed by quarterly improvements in margins. Q1 FY26 showed the strongest operational leverage in the disclosed numbers, with operating EBITDA growth outpacing revenue growth and margins expanding sharply versus the prior year. Segment data shows the hospital business delivering higher growth than diagnostics on revenue, while diagnostics delivered a notable jump in margins. The FY26 exceptional loss disclosure, including the labour codes impact, is also important for readers evaluating how much of reported profit is influenced by exceptional or policy-linked accounting items.

Conclusion

Fortis Healthcare closed FY26 with revenue from operations of ₹9,127.84 crore and profit of ₹1,064.19 crore, alongside an exceptional loss that included a labour-code impact. Quarterly disclosures through FY26 showed sustained revenue growth and margin expansion, with hospitals leading growth and diagnostics improving profitability.